Sleep Loss and Mechanisms of Impaired Glucose Metabolism

This study has been completed.
Sponsor:
Collaborators:
Sunovion
Mclean Hospital
Information provided by (Responsible Party):
John W. Winkelman, MD, PhD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00555750
First received: November 7, 2007
Last updated: November 15, 2013
Last verified: November 2013
Results First Received: May 21, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Basic Science
Condition: Primary Insomnia
Interventions: Drug: eszopiclone
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Eszopiclone nightly active medication (eszopiclone, 3 mg tablet) oral administration ~30 min before bed
Placebo nightly placebo (identical tablet to active medication) oral administration ~30 min before bed

Participant Flow:   Overall Study
    Eszopiclone     Placebo  
STARTED     10     10  
COMPLETED     10     10  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Active active medication administration nightly before bed
Placebo nightly administration of placebo before bed
Total Total of all reporting groups

Baseline Measures
    Active     Placebo     Total  
Number of Participants  
[units: participants]
  10     10     20  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     10     10     20  
>=65 years     0     0     0  
Gender  
[units: participants]
     
Female     2     7     9  
Male     8     3     11  
Region of Enrollment  
[units: participants]
     
United States     10     10     20  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test   [ Time Frame: baseline and 2 months post-treatment ]

2.  Secondary:   Acute Insulin Response to Glucose (AIRg)   [ Time Frame: baseline and 2 months post-treatment ]

3.  Secondary:   Change in Insulin Sensitivity (SI)   [ Time Frame: baseline and 2 months post-treatment ]

4.  Secondary:   Change in Glucose Effectiveness (SG)   [ Time Frame: baseline and 2 months post-treatment ]

5.  Secondary:   Change in HbA1c Levels   [ Time Frame: baseline and 2 months post-treatment ]

6.  Secondary:   Pre-Treatment Leptin Levels   [ Time Frame: baseline ]

7.  Secondary:   Post-treatment Leptin Levels   [ Time Frame: two months post-treatment ]

8.  Secondary:   Pre-treatment Ghrelin Levels   [ Time Frame: baseline ]

9.  Secondary:   Post-treatment Ghrelin Levels   [ Time Frame: 2 months post-treatment ]

10.  Secondary:   Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)   [ Time Frame: baseline and 2 months post-treatment ]

11.  Secondary:   Change in Mean Lapses of Attention   [ Time Frame: baseline and 2 months post-treatment ]

12.  Secondary:   Change in Total Sleep Time as Reported in Sleep Diaries   [ Time Frame: baseline and 2 months post-treatment ]

13.  Secondary:   Change in Total Sleep Time Measured by PSG   [ Time Frame: baseline and 2 months post-treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. John Winkelman, MD, PhD
Organization: Brigham and Women's Hospital
phone: 617-278-0061
e-mail: jwwinkelman@partners.org


Publications:
Buxton OM, Spiegel K and Van Cauter E. Modulation of endocrine function and metabolism by sleep and sleep loss. In: Sleep Medicine, edited by Lee-Chiong M, Carskadon M and Sateia M. Philadelphia: Hanley & Belfus, Inc., 2002, p. 59-69.
Czeisler CA, Winkelman JW and Richardson GS. Disorders of sleep and circadian rhythms. In: Harrison's Principles of Internal Medicine, edited by Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL and Jameson JL. New York: McGraw-Hill,Inc., 2000, p. 1-78.
Dinges DF, Kribbs NB, Bates BL and Carlin MM. A very brief probed-recall memory task: Sensitivity to sleep loss. Sleep Res 22: 330, 1993.
Dinges DF and Powell JW. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behavior Research Methods, Instruments & Computers 17: 652-655, 1985.
Hoddes E, Dement WC and Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiol 9: 150, 1971.


Responsible Party: John W. Winkelman, MD, PhD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00555750     History of Changes
Other Study ID Numbers: BWH-HRC-2005-P-001997, ESRC0004, M01RR002635
Study First Received: November 7, 2007
Results First Received: May 21, 2013
Last Updated: November 15, 2013
Health Authority: United States: Institutional Review Board